AVI Polymers Share Price Hits 5% Upper Circuit as Board Meeting Set for April 27 to Discuss Financial Results, Dividend & Healthcare Tech Expansion

AVI Polymers Limited has announced a board meeting set for April 27, 2026.  

The meeting will focus on key agenda items, including the approval of financial results, dividend declaration, and a strategic move into the healthcare technology sector. 

Key Agenda Items for the Board Meeting 

The board meeting will primarily address the consideration and approval of the audited financial results for the quarter and financial year ending March 31, 2026. This follows a period of significant operational improvement for the company. 

Another major agenda item is the declaration of a dividend. The board will consider recommending a dividend of up to 50% on the paid-up equity share capital for the financial year 2025-26. This proposal is subject to shareholder approval at the upcoming Annual General Meeting. 

Strategic Expansion into Healthcare Technology 

AVI Polymers Limited is also set to discuss a strategic expansion into the healthcare technology sector. This move will be executed through its subsidiary, AVI AI Technologies.  

The company aims to allocate capital effectively to build a diversified, AI-driven digital ecosystem. 

Read More: AVI Polymers Share Price Hits 5% Upper Circuit After Launch of KrishiBuddy Agritech Platform! 

AVI Polymers Share Price Performance  

As of April 20, 2026, at 1:20 PM, AVI Polymers share price on BSE was trading at ₹13.54 up by 4.96% from the previous closing price. 

Conclusion 

The upcoming board meeting of AVI Polymers Limited on April 27, 2026, will cover crucial topics such as financial results, dividend declaration, and strategic expansion into healthcare technology. These discussions reflect the company's ongoing efforts to enhance shareholder value and diversify its business operations. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.